SynthesisWorld journal of gastroenterology2013
Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma.
Synthesis in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients.Scientific reports · 2014Pooled it
- Overview and recent trends of systematic reviews and meta-analyses in hepatology.Clinical and molecular hepatology · 2014Pooled it
- Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients.Journal of cancer research and clinical oncology · 2013Pooled it
- Impact of Tumor Size on Outcomes of Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA): > 3 cm Is No Absolute Contraindication.Cardiovascular and interventional radiology · 2026Article
- Minimally invasive hepatectomyJHEP reports : innovation in hepatology · 2025Article
- Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis.Life (Basel, Switzerland) · 2024Article
- A case of recurrent laryngeal nerve paralysis caused by radiofrequency ablation for mediastinal recurrence of lung cancer.Radiology case reports · 2024Article
- A case of hemoperitoneum after percutaneous radiofrequency ablation in a patient with hepatocellular carcinoma.Forensic science, medicine, and pathology · 2024Article
- Factors associated with increased risk of peritoneal seeding after radiofrequency ablation for hepatocellular carcinoma.Abdominal radiology (New York) · 2023Article
- Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation.Journal of clinical medicine · 2023Review
- 'Potentially curative therapies' for hepatocellular carcinoma: how many patients can actually be cured?British journal of cancer · 2023Article
- Article
- Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis.Surgical endoscopy · 2020Article
- Stratification of risk of recurrence after curative-intent treatment for small hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2019Article
- Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer.Oncology letters · 2018Article
- Preoperative survival calculator for resectable hepatocellular carcinoma.Journal of gastrointestinal oncology · 2018Article
- Article
- Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.OncoTargets and therapy · 2018Article
- Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer.Journal of Cancer · 2018Article
- Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis.American journal of translational research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) represents one of the most common neoplasms worldwide. Surgical resection and local ablative therapies represent the most frequent first lines therapies adopted when liver transplantation can not be offered or is not immediately accessible. Hepatic resection (HR) is currently considered the most curative strategy, but in the last decade local ablative therapies have started to obtain satisfactory results in term of efficacy and, of them, radiofrequency ablation (RFA) is considered the reference standard. An extensive literature review, from the year 2000, was performed, focusing on results coming from studies that directly compared HR and RFA. Qualities of the studies, characteristics of patients included, and patient survival and recurrence rates were analyzed. Except for three randomized controlled trials (RCT), most studies are affected by uncertain methodological approaches since surgical and ablated patients represent different populations as regards clinical and tumor features that are known to affect prognosis. Unfortunately, even the available RCTs report conflicting results. Until further evidences become available, it seems reasonable to offer RFA to very small HCC (< 2 cm) with no technical contraindications, since in this instance complete necrosis is most likely to be achieved. In larger nodules, namely > 2 cm and especially if > 3 cm, and/or in tumor locations in which ablation is not expected to be effective or safe, surgical removal is to be preferred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.